Filing Flows › Medicinova (MNOV) › R&D spending
Medicinova (MNOV) R&D spending by quarter
Medicinova's R&D spending was $900K in Q2 2026 (second quarter 2026), -25% from Q1 2026. Over the last 5 quarters it ranged from $900K (Q2 2026) to $2.0M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $900K | -25% | -55% |
| Q1 2026 | $1.2M | -14% | — |
| Q4 2025 | $1.4M | -7% | — |
| Q3 2025 | $1.5M | -25% | — |
| Q2 2025 | $2.0M | — | — |
Q2 2026 at a glance
Medicinova, Q2 2026: revenue $458K (+241% year over year), operating margin -554.3%, net loss $2.3M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Medicinova's R&D spending?
Medicinova's R&D spending was $900K in Q2 2026 (second quarter 2026), -25% from Q1 2026.
How has Medicinova's R&D spending changed?
Over the last 5 quarters it ranged from $900K (Q2 2026) to $2.0M (Q2 2025).